检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO

Alfonso Yubero,Aranzazu Barquín,Lydia Gaba, Bella Pajares,Piedad Reche, Carmen Salvador,Jesús Alarcón,Luis Manso,Raúl Marquez, Jose Fuentes,Julia Madani, Manuel Costenla,Maria Gutierrez-Toribio,Purificacion Estevez-García,Ana Santaballa,Luisa Sanchez-Lorenzo,Julia Calzas,Ana Herrero,Alvaro Taus,Antonio Gonzalez-Martin

Ovarian cancer（2022）

引用 0|浏览10
暂无评分
关键词
rucaparib access,recurrent ovarian cancer,ovarian cancer,long-term,sub-group
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要